Earnings History Data for Zevra Therapeutics, Inc. (ZVRA) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Zevra Therapeutics, Inc.
KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28-03-2024 | AH | ZVRA | Zevra Therapeutics, Inc. | 207.17 | -0.40 | -0.20 | -0.26 | Zevra Therapeutics GAAP EPS of -$1.30 misses by $0.12, revenue of $27.46M beats by $1.48M [3/28/2024 4:39 PM] |
5.80 | -0.14 (-2.36%) |
5.43 | -0.37 (-6.38%) |
3.89 - 7.28 | 309,258 | 240,000 | 18,334 | ||
| 07-11-2023 | PM | ZVRA | Zevra Therapeutics, Inc. | 157.11 | -0.40 | -0.29 | -0.19 | Zevra Therapeutics GAAP EPS of -$0.40 misses by $0.10, revenue of $2.89M misses by $0.49M [11/7/2023 7:38 AM] |
4.41 | -0.15 (-3.40%) |
4.40 | -0.16 (-3.51%) |
4.05 - 6.44 | 154,898 | 110,000 | 3,532 | ||
| 14-08-2023 | PM | ZVRA | Zevra Therapeutics, Inc. | 169.07 | -0.15 | -0.39 | -0.19 | Zevra Therapeutics GAAP EPS of -$0.15 beats by $0.19, revenue of $8.5M beats by $5.47M [8/14/2023 7:47 AM] |
5.38 | 0.18 (3.46%) |
5.20 | 0.0 (0.00%) |
4.05 - 6.92 | 149,110 | 120,000 | 6,771 | ||
| 15-05-2023 | AH | After the close (May 15) |
ZVRA | Zevra Therapeutics, Inc. | 147.14 | -0.34 | -0.26 | -0.06 | Zevra Therapeutics GAAP EPS of -$0.34 misses by $0.11, revenue of $2.88M beats by $0.19M [5/15/2023 4:14 PM] |
4.68 | 0.32 (7.34%) |
4.30 | -0.06 (-1.38%) |
4.03 - 6.92 | 317,892 | 250,000 | 707 | |
| 07-03-2023 | PM | Before the open (Mar 7) |
ZVRA | Zevra Therapeutics, Inc. | 0.00 | -0.26 | -0.20 | 0.00 | Zevra Therapeutics GAAP EPS of -$0.26 misses by $0.08, revenue of $2.3M misses by $0.8M [3/7/2023 7:49 AM] |
4.25 | -1.09 (-20.47%) |
5.21 | -0.14 (-2.62%) |
4.00 - 6.92 | 1,255,977 | 150,000 | 17,592 | |